Sanofi (SNY) 10-Year Financial Performance & Capital Metrics

SNY • • Industrial / General

HealthcareLarge PharmaBroad-Based Pharmaceutical GiantsGlobal Pharma Diversified Leaders

AboutSanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.Show more

Revenue $44.29B +6.4%
EBITDA $10.84B -4.8%
Net Income $5.56B +3.0%
EPS (Diluted) 2.19 +1.9%
Gross Margin 70.18% +0.8%
EBITDA Margin 24.47% -10.6%
Operating Margin 16.38% -2.1%
Net Margin 12.55% -3.2%
ROE 7.31% +1.1%
ROIC 6.3% +1.4%
Debt/Equity 0.23 -8.5%
Interest Coverage 11.65 -14.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y profit CAGR of 15.1%
✓Strong Piotroski F-Score: 9/9
✓13 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 4.0%
✓Healthy 5Y average net margin of 19.0%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y3.3%

5Y3.31%

3Y4.17%

TTM-6.25%

Profit (Net Income) CAGR

10Y2.39%

5Y15.09%

3Y-3.69%

TTM116.46%

EPS CAGR

10Y2.75%

5Y13.95%

3Y-4.19%

TTM127.22%

ROCE

10Y Avg7.67%

5Y Avg9.47%

3Y Avg7.97%

Latest7.04%

Peer Comparison

Global Pharma Diversified Leaders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AZNAstraZeneca PLC	293.03B	94.51	83.64	18.04%	16.17%	20.45%	2.48%	0.74
GSKGSK plc	100.65B	49.90	40.24	3.46%	17.08%	25.91%	3.55%	1.30
JNJJohnson & Johnson	514.75B	213.65	36.90	4.3%	27.26%	31.69%	3.85%	0.53
NVSNovartis AG	271.72B	141.61	24.12	10.85%	25.53%	32.16%	5.08%	0.71
SNYSanofi	114.36B	47.20	21.55	6.41%	21.16%	12.99%	5.15%	0.23
PFEPfizer Inc.	143B	25.15	17.84	6.84%	15.64%	10.55%	6.88%	0.76
MRKMerck & Co., Inc.	268.7B	108.26	16.06	6.74%	29.63%	36.67%	6.73%	0.83

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	34.86B	34.7B	36.22B	35.68B	37.63B	37.37B	39.17B	40.56B	41.62B	44.29B
Revenue Growth %	0.09%	-0%	0.04%	-0.02%	0.05%	-0.01%	0.05%	0.04%	0.03%	0.06%
Cost of Goods Sold+	10.92B	10.7B	11.61B	11.44B	11.98B	12.16B	12.26B	11.88B	12.63B	13.21B
COGS % of Revenue	0.31%	0.31%	0.32%	0.32%	0.32%	0.33%	0.31%	0.29%	0.3%	0.3%
Gross Profit+	23.94B	24B	24.61B	24.24B	25.65B	25.21B	26.92B	28.68B	28.99B	31.08B
Gross Margin %	0.69%	0.69%	0.68%	0.68%	0.68%	0.67%	0.69%	0.71%	0.7%	0.7%
Gross Profit Growth %	0.1%	0%	0.03%	-0.01%	0.06%	-0.02%	0.07%	0.07%	0.01%	0.07%
Operating Expenses+	18.32B	17.46B	18.8B	19.57B	22.6B	11.1B	18.79B	18.52B	22.03B	23.83B
OpEx % of Revenue	0.53%	0.5%	0.52%	0.55%	0.6%	0.3%	0.48%	0.46%	0.53%	0.54%
Selling, General & Admin	9.38B	9.48B	10.07B	9.86B	9.88B	9.39B	9.55B	8.74B	8.93B	9.18B
SG&A % of Revenue	0.27%	0.27%	0.28%	0.28%	0.26%	0.25%	0.24%	0.22%	0.21%	0.21%
Research & Development	5.08B	5.17B	5.47B	5.89B	6.02B	5.53B	5.69B	6.5B	6.51B	7.39B
R&D % of Revenue	0.15%	0.15%	0.15%	0.17%	0.16%	0.15%	0.15%	0.16%	0.16%	0.17%
Other Operating Expenses	3.85B	2.81B	3.26B	3.81B	6.7B	-3.82B	3.55B	3.28B	6.59B	7.25B
Operating Income+	5.62B	6.53B	5.8B	4.68B	3.05B	14.11B	8.13B	10.16B	6.96B	7.25B
Operating Margin %	0.16%	0.19%	0.16%	0.13%	0.08%	0.38%	0.21%	0.25%	0.17%	0.16%
Operating Income Growth %	-0.07%	0.16%	-0.11%	-0.19%	-0.35%	3.63%	-0.42%	0.25%	-0.32%	0.04%
EBITDA+	9.9B	9.83B	9.49B	8.96B	10.5B	17.78B	11.48B	13.27B	11.39B	10.84B
EBITDA Margin %	0.28%	0.28%	0.26%	0.25%	0.28%	0.48%	0.29%	0.33%	0.27%	0.24%
EBITDA Growth %	0.06%	-0.01%	-0.03%	-0.06%	0.17%	0.69%	-0.35%	0.16%	-0.14%	-0.05%
D&A (Non-Cash Add-back)	4.28B	3.3B	3.69B	4.28B	7.45B	3.67B	3.35B	3.11B	4.43B	3.59B
EBIT	5.8B	6.6B	5.95B	4.9B	3.22B	14.21B	8.19B	10.4B	6.96B	7.45B
Net Interest Income+	-365.37M	-340.47M	-279.47M	-412.12M	-446.57M	-396.41M	-374.24M	-215.84M	17.68M	-165.04M
Interest Income	58.01M	59.03M	53.97M	74.37M	89.71M	34.43M	3.13M	168.96M	530.5M	457.53M
Interest Expense	423.38M	399.5M	333.43M	486.48M	536.27M	430.84M	377.37M	384.8M	512.82M	622.58M
Other Income/Expense	-403M	-720M	-188M	228M	-44M	24M	-289M	-170M	-845M	-494M
Pretax Income+	5.22B	5.81B	5.62B	4.9B	3.01B	14.14B	7.84B	9.99B	6.12B	6.76B
Pretax Margin %	0.15%	0.17%	0.16%	0.14%	0.08%	0.38%	0.2%	0.25%	0.15%	0.15%
Income Tax+	709M	1.32B	1.72B	481M	121M	1.81B	1.56B	1.91B	1.02B	1.2B
Effective Tax Rate %	0.82%	0.81%	1.5%	0.88%	0.92%	0.87%	0.79%	0.84%	0.88%	0.82%
Net Income+	4.29B	4.71B	8.42B	4.31B	2.75B	12.29B	6.22B	8.37B	5.4B	5.56B
Net Margin %	0.12%	0.14%	0.23%	0.12%	0.07%	0.33%	0.16%	0.21%	0.13%	0.13%
Net Income Growth %	-0.02%	0.1%	0.79%	-0.49%	-0.36%	3.46%	-0.49%	0.35%	-0.35%	0.03%
Net Income (Continuing)	4.51B	4.49B	3.89B	4.42B	2.89B	12.33B	6.28B	8.08B	5.1B	5.55B
Discontinued Operations	-124M	314M	4.64B	-13M	-101M	0	0	401M	338M	64M
Minority Interest	161M	170M	169M	159M	174M	146M	350M	368M	313M	350M
EPS (Diluted)+	1.64	1.83	3.36	1.73	1.14	4.91	2.49	3.18	2.15	2.19
EPS Growth %	-0.02%	0.12%	0.84%	-0.49%	-0.34%	3.31%	-0.49%	0.28%	-0.32%	0.02%
EPS (Basic)	1.64	1.83	1.50	1.73	1.14	4.91	2.49	3.19	2.15	2.19
Diluted Shares Outstanding	2.61B	2.57B	2.51B	2.49B	2.5B	2.51B	2.5B	2.5B	2.51B	2.5B
Basic Shares Outstanding	2.61B	2.57B	2.51B	2.49B	2.5B	2.51B	2.5B	2.5B	2.5B	2.5B
Dividend Payout Ratio	0.86%	0.8%	0.44%	0.88%	1.39%	0.32%	0.64%	0.5%	0.82%	0.85%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	24.93B	26.69B	26.35B	24.58B	28.61B	33.7B	30.56B	34.03B	30.66B	42.59B
Cash & Short-Term Investments	9.25B	10.38B	10.31B	6.92B	9.74B	13.91B	10.1B	12.74B	8.71B	7.93B
Cash Only	9.15B	10.27B	10.31B	6.92B	9.74B	13.91B	10.1B	12.74B	8.71B	7.44B
Short-Term Investments	98M	108M	0	0	0	0	0	0	0	486M
Accounts Receivable	8.85B	9.05B	8.68B	9.35B	10.08B	9.95B	9.79B	10.75B	11.04B	10.63B
Days Sales Outstanding	92.69	95.21	87.42	95.61	97.8	97.22	91.19	96.7	96.82	87.6
Inventory	6.52B	6.89B	6.82B	7.48B	7.99B	8.35B	8.71B	8.96B	9.67B	9.43B
Days Inventory Outstanding	217.82	235.08	214.29	238.66	243.58	250.72	259.57	275.24	279.39	260.68
Other Current Assets	13M	31M	210M	363M	299M	958M	1.35B	870M	471M	13.71B
Total Non-Current Assets+	77.39B	77.98B	73.46B	86.83B	84.13B	80.71B	89.68B	92.7B	95.81B	90.21B
Property, Plant & Equipment	9.94B	10.02B	9.58B	9.65B	11.02B	10.56B	11.98B	11.68B	11.81B	11.6B
Fixed Asset Turnover	3.51x	3.46x	3.78x	3.70x	3.42x	3.54x	3.27x	3.47x	3.52x	3.82x
Goodwill	39.56B	40.29B	40.26B	44.23B	44.52B	44.36B	48.06B	49.89B	49.4B	43.38B
Intangible Assets	12.03B	10.88B	13.08B	21.89B	16.57B	18.34B	21.41B	21.64B	24.32B	22.63B
Long-Term Investments	5.35B	5.68B	6.14B	6.17B	5.99B	2.67B	2.91B	3.22B	3.26B	3.26B
Other Non-Current Assets	5.8B	6.45B	104M	271M	595M	600M	731M	882M	588M	1.37B
Total Assets+	102.32B	104.67B	99.81B	111.41B	112.74B	114.41B	120.24B	126.72B	126.46B	132.8B
Asset Turnover	0.34x	0.33x	0.36x	0.32x	0.33x	0.33x	0.33x	0.32x	0.33x	0.33x
Asset Growth %	0.05%	0.02%	-0.05%	0.12%	0.01%	0.01%	0.05%	0.05%	-0%	0.05%
Total Current Liabilities+	16.82B	16.43B	15.46B	17.38B	20.38B	19.25B	21.3B	23.96B	24.19B	29.16B
Accounts Payable	3.82B	4.3B	4.63B	5.04B	5.31B	5.29B	6.18B	6.81B	7.33B	7.55B
Days Payables Outstanding	127.59	146.57	145.62	160.91	161.89	158.95	184.06	209.29	211.81	208.72
Short-Term Debt	3.44B	1.76B	1.27B	2.63B	4.82B	3B	3.45B	4.45B	2.32B	4.21B
Deferred Revenue (Current)	0	0	0	0	0	1000K	1000K	1000K	0	0
Other Current Liabilities	6.61B	7.27B	6.45B	6.98B	7.66B	9.75B	10.61B	11.86B	11.57B	15.13B
Current Ratio	1.48x	1.62x	1.70x	1.41x	1.40x	1.75x	1.44x	1.42x	1.27x	1.46x
Quick Ratio	1.09x	1.20x	1.26x	0.98x	1.01x	1.32x	1.03x	1.05x	0.87x	1.14x
Cash Conversion Cycle	182.91	183.72	156.09	173.36	179.49	188.98	166.69	162.65	164.4	139.57
Total Non-Current Liabilities+	27.29B	30.51B	26.11B	35B	33.25B	31.91B	29.92B	27.61B	27.92B	25.78B
Long-Term Debt	13.07B	16.78B	14.31B	21.99B	20.13B	19.75B	17.12B	14.86B	14.35B	11.79B
Capital Lease Obligations	49M	34M	20M	18M	987M	931M	1.84B	1.9B	1.75B	1.65B
Deferred Tax Liabilities	2.9B	2.29B	1.6B	3.41B	2.29B	1.77B	1.62B	1.84B	1.86B	2.17B
Other Non-Current Liabilities	11.27B	11.41B	10.18B	9.58B	9.84B	9.47B	9.34B	9B	9.96B	10.18B
Total Liabilities	44.11B	46.95B	41.57B	52.37B	53.63B	51.16B	51.21B	51.57B	52.11B	54.94B
Total Debt+	16.55B	18.58B	15.6B	24.64B	25.93B	23.68B	22.41B	21.21B	18.7B	17.91B
Net Debt	7.41B	8.31B	5.29B	17.71B	16.19B	9.76B	12.32B	8.48B	9.99B	10.46B
Debt / Equity	0.28x	0.32x	0.27x	0.42x	0.44x	0.37x	0.32x	0.28x	0.25x	0.23x
Debt / EBITDA	1.67x	1.89x	1.64x	2.75x	2.47x	1.33x	1.95x	1.60x	1.64x	1.65x
Net Debt / EBITDA	0.75x	0.84x	0.56x	1.98x	1.54x	0.55x	1.07x	0.64x	0.88x	0.97x
Interest Coverage	13.28x	16.35x	17.41x	9.61x	5.69x	32.76x	21.53x	26.41x	13.57x	11.65x
Total Equity+	58.21B	57.72B	58.24B	59.03B	59.11B	63.25B	69.03B	75.15B	74.35B	77.86B
Equity Growth %	0.03%	-0.01%	0.01%	0.01%	0%	0.07%	0.09%	0.09%	-0.01%	0.05%
Book Value per Share	22.28	22.43	23.17	23.67	23.65	25.23	27.56	30.02	29.59	31.11
Total Shareholders' Equity	58.05B	57.55B	58.07B	58.88B	58.93B	63.11B	68.68B	74.78B	74.04B	77.51B
Common Stock	2.61B	2.58B	2.51B	2.5B	2.51B	2.52B	2.53B	2.52B	2.53B	2.53B
Retained Earnings	52.01B	51.48B	52.86B	53.11B	51.78B	60.15B	63.01B	66.73B	67.5B	0
Treasury Stock	-298M	-1.5B	-14M	-153M	-9M	-705M	-939M	-706M	-1.18B	-840M
Accumulated OCI	3.73B	5B	2.71B	3.43B	4.51B	782M	3.55B	6.11B	4.88B	70.56B
Minority Interest	161M	170M	169M	159M	174M	146M	350M	368M	313M	350M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	8.92B	7.84B	7.38B	5.55B	7.74B	7.45B	10.52B	10.53B	10.26B	9.08B
Operating CF Margin %	0.26%	0.23%	0.2%	0.16%	0.21%	0.2%	0.27%	0.26%	0.25%	0.21%
Operating CF Growth %	0.16%	-0.12%	-0.06%	-0.25%	0.4%	-0.04%	0.41%	0%	-0.03%	-0.11%
Net Income	4.29B	4.71B	8.43B	4.31B	1.86B	12.31B	6.22B	8.37B	5.4B	5.5B
Depreciation & Amortization	4.28B	3.3B	3.69B	4.28B	7.45B	3.3B	3.35B	3.42B	3.78B	3.59B
Stock-Based Compensation	206M	250M	263M	284M	252M	0	244M	245M	0	0
Deferred Taxes	-1.25B	-542M	-909M	-727M	-1.75B	-221M	-356M	-578M	-1.23B	-802M
Other Non-Cash Items	555M	-458M	-3.98B	-1.03B	355M	-7.62B	-349M	-225M	1.55B	1.42B
Working Capital Changes	1.05B	828M	148M	-1.28B	-419M	-325M	1.41B	-707M	764M	-615M
Change in Receivables	-493M	168M	-529M	-35M	-462M	-134M	185M	-777M	-397M	-28M
Change in Inventory	-466M	-323M	-145M	-701M	-547M	-593M	-357M	-927M	-840M	-477M
Change in Payables	241M	447M	577M	270M	169M	86M	451M	452M	402M	789M
Cash from Investing+	-3.26B	-2.51B	639M	-12.87B	-1.06B	3.59B	-7.3B	-2.08B	-6.2B	-4.41B
Capital Expenditures	-2.77B	-2.08B	-1.96B	-1.98B	-1.82B	-2.11B	-2.04B	-2.2B	-3.25B	-3.23B
CapEx % of Revenue	0.08%	0.06%	0.05%	0.06%	0.05%	0.06%	0.05%	0.05%	0.08%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-123M	206M	3.91B	2.1B	-94M	-113M	-68M	1.47B	-3.87B	1.35B
Cash from Financing+	-3.6B	-4.1B	-7.9B	3.93B	-4.19B	-6.49B	-7.06B	-5.82B	-8.05B	-5.76B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-3.69B	-3.76B	-3.71B	-3.77B	-3.83B	-3.94B	-4.01B	-4.17B	-4.45B	-4.7B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	531M	273M	-15M	-91M	141M	441M	-48M	77M	-63M	-50M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	6.15B	5.75B	5.42B	3.57B	5.93B	5.33B	8.48B	8.32B	8.64B	5.89B
FCF Margin %	0.18%	0.17%	0.15%	0.1%	0.16%	0.14%	0.22%	0.21%	0.21%	0.13%
FCF Growth %	0%	-0.06%	-0.06%	-0.34%	0.66%	-0.1%	0.59%	-0.02%	0.04%	-0.32%
FCF per Share	2.35	2.24	2.16	1.43	2.37	2.13	3.38	3.32	3.44	2.35
FCF Conversion (FCF/Net Income)	2.08x	1.66x	0.88x	1.29x	2.81x	0.61x	1.69x	1.26x	1.90x	1.63x
Interest Paid	404M	401M	347M	412M	379M	315M	334M	380M	559M	587M
Taxes Paid	1.71B	2.1B	1.73B	2.06B	1.7B	2.05B	1.28B	2.45B	2.62B	3.29B

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	7.49%	8.12%	14.52%	7.34%	4.66%	20.09%	9.41%	11.61%	7.22%	7.31%
Return on Invested Capital (ROIC)	6.52%	7.44%	6.72%	5%	3.01%	14.27%	7.9%	9.24%	6.22%	6.3%
Gross Margin	68.68%	69.16%	67.94%	67.95%	68.17%	67.46%	68.72%	70.71%	69.66%	70.18%
Net Margin	12.3%	13.57%	23.24%	12.07%	7.32%	32.9%	15.89%	20.64%	12.98%	12.55%
Debt / Equity	0.28x	0.32x	0.27x	0.42x	0.44x	0.37x	0.32x	0.28x	0.25x	0.23x
Interest Coverage	13.28x	16.35x	17.41x	9.61x	5.69x	32.76x	21.53x	26.41x	13.57x	11.65x
FCF Conversion	2.08x	1.66x	0.88x	1.29x	2.81x	0.61x	1.69x	1.26x	1.90x	1.63x
Revenue Growth	8.94%	-0.47%	4.4%	-1.5%	5.48%	-0.7%	4.83%	3.54%	2.61%	6.41%

Revenue by Geography

	2018	2019	2020	2021	2022	2023
Reportable Geographical Zones	-	-	-	-	-	43.07B
Reportable Geographical Zones Growth	-	-	-	-	-	-
North America	12.19B	-	-	-	-	19.22B
North America Growth	-	-	-	-	-	-
Europe	-	-	-	9.76B	10B	10.39B
Europe Growth	-	-	-	-	2.46%	3.93%
FRANCE	2.32B	-	-	-	-	2.38B
FRANCE Growth	-	-	-	-	-	-
Europe 1	-	8.85B	9.15B	-	-	-
Europe 1 Growth	-	-	3.38%	-	-	-
Reportable geographical zones	34.46B	-	-	-	-	-
Reportable geographical zones Growth	-	-	-	-	-	-
Other Countries	13.49B	-	-	-	-	-
Other Countries Growth	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Sanofi (SNY) has a price-to-earnings (P/E) ratio of 21.6x. This is roughly in line with market averages.

Growth & Financials

Sanofi (SNY) reported $43.13B in revenue for fiscal year 2024. This represents a 23% increase from $35.06B in 2011.

Sanofi (SNY) grew revenue by 6.4% over the past year. This is steady growth.

Yes, Sanofi (SNY) is profitable, generating $9.13B in net income for fiscal year 2024 (12.6% net margin).

Dividend & Returns

Yes, Sanofi (SNY) pays a dividend with a yield of 3.98%. This makes it attractive for income-focused investors.

Sanofi (SNY) has a return on equity (ROE) of 7.3%. This is below average, suggesting room for improvement.

Sanofi (SNY) generated $2.09B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...